https://orcid.org/0000-0003-0908-3597
Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Paskorn Sritipsukho, Thana Khawcharoenporn, Boonying Siribumrungwong, Pansachee Damronglerd, Nuntra Suwantarat, Araya Satdhabudha, Chanapai Chaiyakulsil, Phakatip Sinlapamongkolkul, Auchara Tangsathapornpong, Pornumpa Bunjoungmanee, Sira Nanthapisal, Chamnan Tanprasertkul, Naiyana Sritipsukho, Chatchai Mingmalairak, Anucha Apisarnthanarak & Pichaya Tantiyavarong. (2023) Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?. Emerging Microbes & Infections 12:1.
Read now
Read now
Hazal Cansu Çulpan, Sümeyye Nur Aydın, Abdulkerim Uygur, Uğurcan Sayılı, Erkam Şeker, İ̇lker İnanç Balkan, Rıdvan Karaali, Beyhan Budak, Yılmaz Keskindemirci, Neşe Saltoğlu & Günay Can. (2023) Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers. Human Vaccines & Immunotherapeutics 19:3.
Read now
Read now
Moe H. Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh & Amit Srivastava. (2023) Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Articles from other publishers (33)
Vivek Jason Jayaraj, Masliyana Husin, Jing Lian Suah, Peter Seah Keng Tok, Azahadi Omar, Sanjay Rampal & Sheamini Sivasampu. (2024) Effectiveness of COVID-19 vaccines among children 6–11 years against hospitalization during Omicron predominance in Malaysia. Scientific Reports 14:1.
Crossref
Crossref
Cheng-Yi Lee, Hung-Wei Kuo, Yu-Lun Liu, Jen-Hsiang Chuang & Jih-Haw Chou. (2024) Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan. Emerging Infectious Diseases 30:3.
Crossref
Crossref
Peter Seah Keng Tok, Kong Yeow Kang, Sock Wen Ng, Norazida Ab Rahman, Muhammad Aminul Syahmi, Mohan Dass Pathmanathan, Maheshwara Rao Appannan, Kalaiarasu M. Peariasamy & Sheamini Sivasampu. (2024) Post COVID-19 condition among adults in Malaysia following the Omicron wave: A prospective cohort study. PLOS ONE 19:1, pages e0296488.
Crossref
Crossref
Karim Yaqub Ibrahim, Raquel Megale Moreira, Carolina Ferreira dos Santos, Tânia Mara Varejão Strabelli, Juliana de Cássia Belizário, Maria Isabel de Moraes Pinto, Ana Karolina Barreto Berselli Marinho, Juliana Marquezi Pereira, Liliane Saraiva de Mello, Mauricio Cesar Ando, Vitor Gabriel Lopes da Silva, Paula Keiko Sato, Marcos Alves de Lima, João Italo Dias França, Ana Paula Loch, Karina Takesaki Miyaji, Vanessa Infante, Alexander Roberto Precioso & Ana Marli Christovam Sartori. (2024) Immunogenicity of COVID-19 adsorbed inactivated vaccine (CoronaVac) and additional doses of mRNA BNT162b2 vaccine in immunocompromised adults compared with immunocompetent persons. Revista do Instituto de Medicina Tropical de São Paulo 66.
Crossref
Crossref
Marcelo Wolff, Paulo Charpentier, Andrea Canals, Cecilia Vial, Juan Hormazábal, Jimena Cortés & Macarena Silva. (2024) Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study. Vaccine 42:3, pages 671-676.
Crossref
Crossref
S. Cankat, M. U. Demael & L. Swadling. (2023) In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. Cellular & Molecular Immunology 21:2, pages 103-118.
Crossref
Crossref
Sabir Meah, Xu Shi, Lars G. Fritsche, Maxwell Salvatore, Abram Wagner, Emily T. Martin & Bhramar Mukherjee. (2023) Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study. Science Advances 9:51.
Crossref
Crossref
Md. Obaidur Rahman, Taro Kamigaki, Moe Moe Thandar, Rei Haruyama, Fangyu Yan, Miho Shibamura-Fujiogi, July Khin Maung Soe, Md. Rafiqul Islam, Daisuke Yoneoka, Reiko Miyahara, Erika Ota & Motoi Suzuki. (2023) Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis. BMJ Open 13:12, pages e076892.
Crossref
Crossref
Norazida Ab Rahman, Ming Tsuey Lim, Fei Yee Lee, Wee Kee Wo, Hee Sheong Yeoh, Kalaiarasu M. Peariasamy, Sheamini Sivasampu, Azuana Ramli, Sing Chet Lee, Sim Mei Choo, Maheshwara Rao Appanan, Teck Long King, Chia How Yen, Emelyne Bani Anak Jam, Fatihah Mahmud, Fariz Safhan Mohamad Nor, Muhammad Hazrul Badrul Hisham, Siti Nurhafizah Saharudin, Nor Aliya Ayub, Raj Kumar Sevalingam, Rashidah Bahari, Nor Nadziroh Ibrahim, Nurain Mohd Noor, Lisa Mohamed Nor, Nurul Huda Zainal Abidin, Hin Seng Wong, Siti Nur Akmal Ghazali, Nurul Afifah Rozkhaidi, Norzubaidatulhikmah Shaduqi, Hanisah Hossain, Jeannette Jieni Lay & Nor Azizah Mohamad Nazri. (2023) Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study. Scientific Reports 13:1.
Crossref
Crossref
Soledad González, Santiago Olszevicki, Alejandra Gaiano, Martín Salazar, Lorena Regairaz, Ana Nina Varela Baino, Erika Bartel, Teresa Varela, Veronica V. González Martínez, Santiago Pesci, Lupe Marín, Juan Ignacio Irassar, Leticia Ceriani, Enio Garcia, Nicolás Kreplak, Elisa Estenssoro & Franco Marsico. (2023) Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study. The Lancet Regional Health - Americas 27, pages 100607.
Crossref
Crossref
Wandong Liu, Juan Wang, Suyun Wang, Kairui Yue, Yu Hu, Xiaochun Liu, Lihao Wang, Shengbiao Wan & Ximing Xu. (2023) Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease. Bioorganic Chemistry 140, pages 106830.
Crossref
Crossref
Di Liu, Siyang Feng, Feng Sha, Yuxue Liao, Xu Xie, Fang Huang, Dongfeng Kong, Zhen Zhang, Zhigao Chen, Nixuan Chen, Wei Gao, Tiejian Feng, Ziyi Zhao, Bingli Li, Ying Li, Fengcai Zhu, Zhirong Yang, Qiuying Lv, Zijian Feng & Jinling Tang. (2023) Inactivated SARS-CoV-2 Vaccine Booster Against Omicron Infection Among Quarantined Close Contacts. JAMA Network Open 6:10, pages e2339507.
Crossref
Crossref
Kaixin Guo, Peng Ni, Shuailei Chang, Yuefei Jin, Guangcai Duan & Rongguang Zhang. (2023) Effectiveness of mRNA vaccine against Omicron-related infections in the real world: A systematic review and meta-analysis. American Journal of Infection Control 51:9, pages 1049-1055.
Crossref
Crossref
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Lars Christian Lund, Christian Holm Hansen, Mia Aakjær, Jesper Kjær, Catherine Cohet, Mathijs Goossens, Morten Andersen, Jesper Hallas, Hinta Meijerink, Rickard Ljung & Anders Hviid. (2023) Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ, pages e074325.
Crossref
Crossref
Harvey Palalay, Riddhi Vyas & Barbara Tafuto. (2023) Real-world effectiveness of mRNA COVID-19 vaccines in the elderly during the Delta and Omicron variants: Systematic review. World Journal of Meta-Analysis 11:5, pages 167-180.
Crossref
Crossref
Yasemin Genç Bahçe, Ömer Acer & Osman Özüdoğru. (2023) Effectiveness of Inactivated and mRNA COVID-19 Vaccines Against SARS-CoV-2 Infection, Severe Disease and Mortality in the Geriatric Population. Current Microbiology 80:6.
Crossref
Crossref
Peng Yang, Bianli Dang, Wen Kang, Xiaofeng Li, Tianping Wang, Ruijuan Li, Meijuan Peng, Yushen Liu, Linxu Wang, Yan Cheng, Suhuai Yu, Min Wei, Han Gao, Wenzhen Kang & Lei Shang. (2023) Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China. Frontiers in Public Health 11.
Crossref
Crossref
Su Lan Yang, Adiratna Mat Ripen, Jen Ven Lee, Karina Koh, Chia How Yen, Avinash Kumar Chand, Nur Aisyah Binti Abdul Rahim, Varaalakshmy Gokilavanan, Nik Nur Eliza Binti Mohamed, Raj Kumar A∕L Sevalingam & Kalaiarasu M. Peariasamy. (2023) Time from last immunity event against infection during Omicron-dominant period in Malaysia. International Journal of Infectious Diseases 128, pages 98-101.
Crossref
Crossref
Jiayue Wan, Casey L. Cazer, Marin E. Clarkberg, Shane G. Henderson, Scarlett E. Lee, Genevive R. Meredith, Marwan Osman, David B. Shmoys & Peter I. Frazier. (2023) Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study. PLOS Medicine 20:1, pages e1004153.
Crossref
Crossref
Yuri Amemiya, Tianwen Li & Hiroshi Nishiura. (2023) Age-dependent final size equation to anticipate mortality impact of COVID-19 in China. Mathematical Biosciences and Engineering 20:6, pages 11353-11366.
Crossref
Crossref
Congshan Jiang, Kaichong Jiang, Xiaowei Li, Ning Zhang, Wenhua Zhu, Liesu Meng, Yanmin Zhang & Shemin Lu. (2023) Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. Journal of Pharmaceutical Analysis 13:1, pages 1-10.
Crossref
Crossref
Julien Favresse, Constant Gillot, Jean‐Louis Bayart, Clara David, Germain Simon, Loris Wauthier, Mélanie Closset, Jean‐Michel Dogné & Jonathan Douxfils. (2022) Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. Journal of Medical Virology 95:1.
Crossref
Crossref
Yiyi Xu, Huiqi Li, Brian Kirui, Ailiana Santosa, Magnus Gisslén, Susannah Leach, Björn Wettermark, Lowie E. G. W. Vanfleteren & Fredrik Nyberg. (2022) Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. Vaccines 10:12, pages 2074.
Crossref
Crossref
Zhiyuan Chen, Xiaowei Deng, Liqun Fang, Kaiyuan Sun, Yanpeng Wu, Tianle Che, Junyi Zou, Jun Cai, Hengcong Liu, Yan Wang, Tao Wang, Yuyang Tian, Nan Zheng, Xuemei Yan, Ruijia Sun, Xiangyanyu Xu, Xiaoyu Zhou, Shijia Ge, Yuxia Liang, Lan Yi, Juan Yang, Juanjuan Zhang, Marco Ajelli & Hongjie Yu. (2022) Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study. The Lancet Regional Health - Western Pacific 29, pages 100592.
Crossref
Crossref
Wei-Yu Chi, Yen-Der Li, Hsin-Che Huang, Timothy En Haw Chan, Sih-Yao Chow, Jun-Han Su, Louise Ferrall, Chien-Fu Hung & T.-C. Wu. (2022) COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. Journal of Biomedical Science 29:1.
Crossref
Crossref
Nesrin Gareayaghi, Mehmet Demirci, Dogukan Ozbey, Ferhat Dasdemir, Harika Oyku Dinc, Ilker Inanc Balkan, Suat Saribas, Neşe Saltoglu & Bekir Kocazeybek. (2022) Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose. Vaccines 10:10, pages 1672.
Crossref
Crossref
Yinchang Chen, Zhende Wang, Feng Li, Jingyu Ma, Jie Zhang, Yunpeng Chen & Ting Zhang. (2022) Comparison of COVID-19 and seasonal influenza under different intensities of non-pharmaceutical interventions and vaccine effectiveness. Frontiers in Public Health 10.
Crossref
Crossref
Jeadran Malagón-Rojas, Marcela Mercado-Reyes, Yesith G. Toloza-Pérez, Marisol Galindo, Ruth M. Palma, Jenssy Catama, Juan F. Bedoya, Eliana L. Parra-Barrera, Ximena Meneses, Juliana Barbosa, Pilar Tavera-Rodríguez, Andrea Bermúdez-Forero & Martha Lucía Ospina-Martínez. (2022) Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022. Vaccines 10:10, pages 1609.
Crossref
Crossref
Su Lan Yang, Hoon Shien Teh, Jing Lian Suah, Masliyana Husin & Wen Yea Hwong. (2022) SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period. The Lancet Regional Health - Western Pacific 26, pages 100572.
Crossref
Crossref
Yajuan Zhu, Shuang Liu & Dingmei Zhang. (2022) Effectiveness of COVID-19 Vaccine Booster Shot Compared with Non-Booster: A Meta-Analysis. Vaccines 10:9, pages 1396.
Crossref
Crossref
Dorota Zarębska-Michaluk, Chenlin Hu, Michał Brzdęk, Robert Flisiak & Piotr Rzymski. (2022) COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. Vaccines 10:8, pages 1223.
Crossref
Crossref
Chin Shern Lau, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu & Tar Choon Aw. (2022) Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore. Antibodies 11:2, pages 38.
Crossref
Crossref
Theresia Santi, Lina Kamarga, Baringin De Samakto & Juandy Jo. (2022) SARS-CoV-2 Breakthrough Infection after mRNA-1273 Booster among CoronaVac-Vaccinated Healthcare Workers. Infection & Chemotherapy 54:4, pages 774.
Crossref
Crossref